By: Arshad M. Khanani, MD, MA; and Veeral Sheth, MD
Arshad M. Khanani, MD, MA; and Veeral Sheth, MD, discuss the current treatment regimens of patients with neovascular AMD and compare how disease management may change with therapies expected to gain FDA approval in the near future.
This continuing medical education activity is supported through educational grant from Genentech.
Upon completion of this activity, the participant should be able to:
Provided by Evolve Medical Education
Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Arshad M. Khanani, MD, MA
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno School of Medicine
Reno, Nevada
Veeral Sheth, MD
Director of Clinical Research
Board Certified Ophthalmologist and Retinal Surgeon
Clinical Assistant Professor
University of Illinois at Chicago
Chicago, IL
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Arshad M. Khanani, MD, MA; and or spouse; has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerpio, Allegro, Allergan, Graybug, Genentech, Gyroscope, Kodiak, Notal Vision, Novartis, Opthea, Orbit BioMedical, Oxurion, Polyphotonix, Recens Medical, and Regenexbio. Grant/Research Support: Advernum, Aerpio, Allergan, Gemini, Genentech, Graybug, Gyroscope, Kodiak, Novartis, Opthea, Oxurion, Recens Medical, and Regenxbio. Speaker’s Bureau: Allergan, Genentech, and Novartis.
Veeral Sheth, MD, and/or spouse, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support: Allergan, Alimera, Genentech, Novartis and Regeneron Pharmaceuticals. Speaker’s Bureau: Alimera, Eyepoint, Genentech, and Novartis.
The staff and planners at Evolve Medical Education have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.